PerkinElmer and Procognia to Offer Breakthrough Protein Array Platform
U-c fingerprint technology requires no sample purification or pretreatment, and allows the quantitative analysis of 20 samples in approximately three hours. In addition, glycosylation analysis throughout the therapeutic protein discovery, development and manufacturing process will bring biopharmaceutical companies closer to satisfying the FDA's PAT (Process Analytical Technology) initiative. This technology is focused on reducing the time and cost of producing higher quality biopharmaceuticals.
"Procognia is a leader in proteomic technologies and together with PerkinElmer's extensive capabilities, we can now offer the industry's first complete high-throughput, high-resolution glycoanalysis platform for academic, biotech, and pharmaceutical customers," said Peter Coggins, PhD., president, PerkinElmer Life and Analytical Sciences.
"We believe we can accelerate adoption of Procognia's U-c fingerprint technology and firmly establish it as the gold standard in the monitoring and control of glycosylation of proteins by teaming with a global life sciences solutions provider like PerkinElmer," said Ron Long, CEO of Procognia Ltd.
Most read news
Topics
Organizations
Other news from the department research and development
These products might interest you
Kjel- / Dist Line by Büchi
Kjel- and Dist Line - steam distillation and Kjeldahl applications
Maximum accuracy and performance for your steam distillation and Kjeldahl applications
AZURA Purifier + LH 2.1 by KNAUER
Preparative Liquid Chromatography - New platform for more throughput
Save time and improve reproducibility during purification
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.